logo.jpg
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
July 13, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
May 25, 2021 08:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
FBI LOGO TM.png
Central Nervous System Treatment Market to Reach USD 166.53 Billion with a CAGR of 9.4% by 2028; Rising Cases of Neurological Disorders to Propel Growth: states Fortune Business Insights™
March 22, 2021 05:51 ET | Fortune Business Insights
Pune, India, March 22, 2021 (GLOBE NEWSWIRE) -- The global central nervous system treatment market size is expected to reach USD 166.53 billion by 2028, exhibiting a CAGR of 9.4% during the forecast...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 17, 2021 07:00 ET | Praxis Precision Medicines, Inc.
PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021 Innovative...
Nerve Control 911 Reviews: Negative Side Effects or Legit Ingredients? 2021 Review
March 12, 2021 13:56 ET | 2021Review.com
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- Nerve Control 911 is a daily remedy for the central nervous system, supporting the communication to the organs and muscles. The formula is easy to take...
Logo 1.png
Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
January 28, 2021 08:05 ET | Aeterna Zentaris Inc
- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis...
FBI LOGO TM.png
Report 2021, Central Nervous System Treatment Market Size, Share, Growth, Trends, Analysis, Revenue, Forecast Report – 2020-2027
January 25, 2021 06:25 ET | Fortune Business Insights
Pune, India, Jan. 25, 2021 (GLOBE NEWSWIRE) -- The global central nervous system treatment market size is expected to gain momentum in the forthcoming years. This is attributable to the increasing...
CNS Pharmaceuticals logo.png
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
December 28, 2020 08:00 ET | CNS Pharmaceuticals, Inc.
HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...
CNS Pharmaceuticals logo.png
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy
November 24, 2020 08:00 ET | CNS Pharmaceuticals, Inc.
HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...
gmi logo.jpg
Rare Disease Treatment Market revenue to cross USD 317 Bn by 2026: Global Market Insights, Inc.
November 19, 2020 04:00 ET | Global Market Insights, Inc
Selbyville, Delaware, Nov. 19, 2020 (GLOBE NEWSWIRE) -- According to latest report “Rare Disease Treatment Market by Drug Type (Biologics, Non-biologics), Therapeutic Area (Cancer, Blood-related...